GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2008

Agendia Offers Prognostic Tool for Breast Cancer

  • Agendia released TargetPrint®, a test that quantitatively determines the gene expression levels of the estrogen receptor, progesterone receptor, and HER2 in breast cancer tumor biopsies.

    TargetPrint runs on Agendia’s high-density chip, which received market clearance last month from the FDA

    “The test’s results give a precise molecular readout of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient,” says Richard A. Bender, M.D., CMO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?